Wegener's Granulomatosis Clinical Trial
Official title:
Wegener's Granulomatosis Etanercept Trial (WGET)
This study will determine if the drug etanercept, also called Enbrel, is effective in
producing and maintaining remission (reduction of disease symptoms) of Wegener's
granulomatosis (WG). Etanercept blocks the action of tumor necrosis factor-alpha, a
substance that may be involved in inflammatory conditions such as WG. Eight clinical centers
around the United States will enroll 181 people who have WG. Patients will have an equal
chance to receive either etanercept or placebo (inactive treatment). We will treat patients
with standard medications for WG in addition to either etanercept or placebo. We will treat
all patients with tapering doses of corticosteroids.
After the patients' disease is controlled (in remission), we will reduce the dosages of the
standard medications to lower the risk of side effects associated with these drugs. During
the study, we will collect and save blood and tissues samples from patients and use the
samples to address other medical questions, such as the cause of WG and factors that lead to
disease progression.
Status | Completed |
Enrollment | 181 |
Est. completion date | March 2003 |
Est. primary completion date | March 2003 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 11 Years and older |
Eligibility |
Inclusion Criteria: - Minimum weight of 40 kg. - Diagnosis of WG, excluding infections, malignancies, systemic autoimmune disorders, and other forms of vasculitis that may mimic WG. - At least two of the five modified American College of Rheumatology (ACR) criteria for a diagnosis of WG. The modified ACR criteria are: (1) nasal or oral inflammation, defined as the development of painful or painless oral ulcers or purulent or bloody nasal discharge; (2) abnormal chest radiograph, defined as the presence of nodules, fixed infiltrates, or cavities; (3) active urinary sediment, defined as microscopic hematuria (> 5 red blood cells per high-power field) or red blood cell casts; (4) granulomatous inflammation on biopsy, defined as histologic changes showing granulomatous inflammation within the wall of an artery or in the perivascular or extravascular area (artery or arteriole); and (5) positive serum ELISA for ANCAs (anti-neutrophil cytoplasmic antibodies) directed at PR-3. - Birmingham Vasculitis Activity Score (BVAS) score 3 or greater within 28 days of randomization. This may include either the presence of one or more major items (3 points each) or the presence of three or more minor items (1 point each). - Willingness and ability, with the assistance of a caregiver if necessary, to comply with treatment and followup procedures. - Willingness of men and women of childbearing potential to practice an adequate method of birth control during the study and for 3 months afterwards. - Willingness to limit alcohol consumption to one alcoholic drink per week while taking methotrexate. - Willingness to refrain from breast-feeding during the study and for 3 months afterwards. - Collection of all baseline data within 14 days prior to randomization. - Signed consent statement. Exclusion Criteria: - Presence of an active systemic infection. - White blood cell count less than 4,000/mm cubed or a platelet count less than 120,000/mm cubed. - Creatinine greater than 2.0 mg/dL secondary to non-WG causes (e.g., hypertensive nephropathy) for a patient with limited disease. - Known acute or chronic liver disease. - History of multiple sclerosis or other neurological symptoms suggesting a demyelinating syndrome. - Current evidence of malignancy or malignancy diagnosed within 5 years of study entry. Patients with squamous or basal cell carcinomas of the skin may be enrolled if they have received curative surgical treatment. - Positive serum pregnancy test for women of childbearing potential. - Previous treatment with specific therapies directed against tumor necrosis factor, e.g., etanercept or infliximab. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan | Ann Arbor | Michigan |
United States | Johns Hopkins University | Baltimore | Maryland |
United States | Boston University | Boston | Massachusetts |
United States | Cleveland Clinic Foundation | Cleveland | Ohio |
United States | Duke University | Durham | North Carolina |
United States | Beth Israel Medical Center | New York | New York |
United States | Mayo Clinic | Rochester | Minnesota |
United States | University of California, San Francisco | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | FDA Office of Orphan Products Development |
United States,
Merkel PA, Lo GH, Holbrook JT, Tibbs AK, Allen NB, Davis JC Jr, Hoffman GS, McCune WJ, St Clair EW, Specks U, Spiera R, Petri M, Stone JH; Wegener's Granulomatosis Etanercept Trial Research Group. Brief communication: high incidence of venous thrombotic e — View Citation
Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, Davis JC, Ytterberg SR, St Clair EW, McCune WJ, Specks U, Allen NB, Luqmani RA, Stone JH; WGET Research Group. Damage caused by Wegener's granulomatosis and its treatment: prospective data from — View Citation
Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, Specks U, Allen NB, Davis JC, Spiera RF, Calabrese LH, Wigley FM, Maiden N, Valente RM, Niles JL, Fye KH, McCune JW, St Clair EW, Luqmani RA; International Network for the Study of the Systemic Vasculitides (INSSYS). A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum. 2001 Apr;44(4):912-20. — View Citation
Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, Specks U, Merkel PA, Spiera R, Davis JC, St Clair EW, McCune WJ, Ytterberg SR, Allen NB, Hoffman GS; Wegener's Granulomatosis Etanercept Trial Research Group. Solid malignancies among pa — View Citation
Stone JH, Rajapakse VN, Hoffman GS, Specks U, Merkel PA, Spiera RF, Davis JC, St Clair EW, McCune J, Ross S, Hitt BA, Veenstra TD, Conrads TP, Liotta LA, Petricoin EF 3rd; Wegener's Granulomatosis Etanercept Trial Research Group. A serum proteomic approac — View Citation
Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum. 2001 May;44(5):1149-54. — View Citation
Stone JH; Wegener's Granulomatosis Etanercept Trial Research Group. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum. 2003 Aug;48(8):2299-309. — View Citation
WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Control Clin Trials. 2002 Aug;23(4):450-68. — View Citation
Wung PK, Holbrook JT, Hoffman GS, Tibbs AK, Specks U, Min YI, Merkel PA, Spiera R, Davis JC, St Clair EW, McCune J, Ytterberg SR, Allen NB, Stone JH; WGET Research Group. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients in the two treatment arms who achieve sustained remissions as measured by the Birmingham Vasculitis Activity Score (BVAS) for WG | Measured at study completion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00747461 -
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")
|
Phase 4 | |
Completed |
NCT00072592 -
An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
|
Phase 1 | |
Recruiting |
NCT02593565 -
Vasculitis Pregnancy Registry
|
||
Completed |
NCT01167491 -
Study of One Protein Implicated in Wegener Disease
|
N/A | |
Completed |
NCT00307593 -
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
|
N/A | |
Active, not recruiting |
NCT00006055 -
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
|
N/A | |
Completed |
NCT00001473 -
Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides
|
N/A | |
Terminated |
NCT01408836 -
Plasma Exchange for Renal Vasculitis
|
Phase 2/Phase 3 | |
Completed |
NCT00001256 -
Steroids and Methotrexate to Treat Systemic Vasculitis
|
Phase 2 | |
Completed |
NCT00040248 -
Daclizumab to Treat Wegener's Granulomatosis
|
Phase 2 | |
Completed |
NCT00307671 -
Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
|
Phase 4 | |
Completed |
NCT01988506 -
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
|
Phase 2 | |
Recruiting |
NCT01066208 -
American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
|
N/A | |
Completed |
NCT00104299 -
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
|
Phase 2/Phase 3 | |
Completed |
NCT00753103 -
Anti-Cytokine Therapy for Vasculitis
|
Phase 2 | |
Completed |
NCT02176070 -
Reproductive Health in Men and Women With Vasculitis
|
N/A | |
Completed |
NCT00468208 -
Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
|
Phase 1/Phase 2 | |
Completed |
NCT00004567 -
Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes
|
Phase 2 | |
Completed |
NCT00001901 -
Etanercept to Treat Wegener's Granulomatosis
|
Phase 2 | |
Completed |
NCT00430105 -
Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides
|
Phase 2/Phase 3 |